25th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium
At the conclusion of this activity, participants will be able to:
- State the clinical effects of novel experimental agents; including but not limited to immunotherapeutic approaches other than PD1 and CTLA4 checkpoint inhibitors, nuclear hormone receptor modulating agents, and epigenetic targeted drugs;
- Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches including novel PET tracer imaging and circulating tumor DNA assays;
- Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
- Discuss advances in the use of systemic therapies for cancer; including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations.
Agenda subject to change.
WANT TO KNOW MORE?
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact Debbie Stoit via email at email@example.com.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
UNIVERSITY OF CHICAGO COURSE DIRECTORS
Fred C. Buffett Professor of Medicine and Surgery
Dean for Clinical Research
Deputy Director, Comprehensive Cancer Center
Professor of Medicine
Director, Leukemia Program
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
JOINING THE VIRTUAL CONFERENCE
If you need assistance joining the session or experience other technical issues, contact technical support.
At the end of the course, the credit claiming process will unlock. Return to this page and click on "Complete Activity" to proceed.
Please Note: Requests to claim MOC Part II credit must be made within one month to report to ABIM. Requests to claim AMA PRA Category 1 Credit™ after three months will be subject to additional fees.